Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis

INTRODUCTION: Teriflunomide, indicated for the treatment of relapsing–remitting multiple sclerosis, is contraindicated in pregnancy based on signs of developmental toxicity in the offspring of rats and rabbits; developmental toxicity has also been observed in preclinical studies of other disease-mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieseier, Bernd C., Benamor, Myriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386431/
https://www.ncbi.nlm.nih.gov/pubmed/26000229
http://dx.doi.org/10.1007/s40120-014-0020-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386431/
https://www.ncbi.nlm.nih.gov/pubmed/26000229
http://dx.doi.org/10.1007/s40120-014-0020-y

Ejemplares similares